

Disclosures:

Funding: Celgene Corporation

Authors:

KWS: consulting for Biogen, Celgene, Genzyme, Merck, Novartis, Ono Pharma, Roche, Synthon, and Teva.

LS: consulting for AbbVie, Atreca, Celgene, Novartis, Teva, Tolerion, and EMD Serono, and research support from Atara, Biogen, and Celgene.

GC: compensation for consulting and/or speaking activities from Almirall, Biogen, Celgene, EXCEMED, Forward Pharma, Genzyme, Merck, Novartis, Roche, Sanofi, and Teva.

ABO: participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Atara Biotherapeutics, Biogen, BMS-Celgene, EMD Serono, Novartis, Roche-Genentech, and Sanofi Genzyme.

DLA: personal fees for consulting and/or grants from Albert Charitable Trust, Biogen, Celgene, F. Hoffmann-La Roche, Frequency Therapeutics, MedDay, Merck Serono, Novartis, Sanofi-Aventis, and an equity interest in NeuroRx Research.

HPH: personal fees for consulting, serving on steering committees, and speaking from Bayer Healthcare, Biogen, Celgene, GeNeuro, Genzyme, Merck, MedImmune, Novartis, Octapharma, Roche, Sanofi, and Teva.

XM: speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 3 years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, EXCEMED, Genzyme, MedDay, Merck, MSIF, Nervgen, NMSS, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceutical, and TG Therapeutics.

EKH: personal compensation for consulting and speaking for Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, and Teva, and is supported by Czech Ministry of Education, project PROGRES Q27/LF1.

JKS, HL, NM, DS: employees of Bristol-Myers Squibb Company.

LK's institution (University Hospital Basel) has received in the last 3 years the following, which was used exclusively for research support: steering committee, advisory board, consultancy fees, and support of educational activities from Actelion, Allergan, Almirall, Baxalta, Bayer, Biogen, Celgene, CSL Behring, Desitin, EXCEMED, Eisai, Genzyme, Japan Tobacco, Merck, Minoryx, Novartis, Pfizer, F. Hoffmann-La Roche, Sanofi Aventis, Santhera, Teva, and license fees for Neurostatus-UHB products; and the Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, European Union, Innosuisse, Novartis, Roche Research Foundations, Swiss MS Society, and Swiss National Research Foundation.

JAC: personal compensation for consulting for Adamas, Convelo, and Mylan, and serving as an Editor of *Multiple Sclerosis Journal*. **BACC:** personal compensation for consulting for Akili, Alexion, Biogen, EMD Serono, Novartis, and TG Therapeutics.